Takeda | Protocol Vedolizumab-4054 (ExiGem) - Currently Recruiting
Molecule: Vedolizumab and Tofacitinib
Study Title:
An Open-Label, Phase 4, Single-Arm, Multicenter Study to Evaluate the Induction of Response and Remission of Vedolizumab Dual Targeted Therapy with Tofacitinib in Adult Patients with Moderately to Severely Active Ulcerative Colitis
Spyre Therapeutics, Inc | Protocol PY123-201 (The SKYLINE-UC Study) - Pending Approbation
Molecule: Add on humanized antibodies
Study Title:
Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis